In June of this year (2011), JDRF announced a new research collaboration to support the development of a vaccine which may help better treat and potentially prevent type 1 diabetes. The partnership with Selecta Biosciences will see JDRF provide expertise and financial support, with the goal of applying Selecta’s vaccine technology toward the development of vaccines for type 1 diabetes.
Selecta is working on a type of therapy called an ‘antigen-specific tolerogenic vaccine’. This is designed to specifically target the parts of the immune system that cause type 1 diabetes, without damaging the rest of the immune system. In addition to its potential in preventing type 1 diabetes, this type of diabetes vaccine could have other benefits. For example, they could be used in conjunction with other therapies to preserve remaining beta cell function in individuals recently diagnosed with type 1 diabetes. It may also help with regeneration and replacement therapies, and be used to protect newly regenerated or transplanted insulin-producing beta cells in established type 1 diabetes
JDRF’s Chief Scientific Officer said: “We believe vaccine research is one of the most promising approaches to prevent or halt the beta cell-specific autoimmunity in type 1 diabetes. And we are excited to be teaming up with Selecta to support the development of this next-generation of vaccine technology.”
The research collaboration agreement between JDRF and Selecta is part of JDRF’s Industry Discovery and Development Partnership (IDDP) program. Through this, JDRF partners with pharmaceutical, biotechnology, and medical device companies to prioritise and speed the discovery, development, and delivery of therapies and devices for type 1 diabetes.